

	2021							
	Feb	Mar	Apr	May	Jun	Jul	Aug	
BNT162b2								
Market approval								
Approval for individuals aged ≥ 16 years								
Approval for individuals aged 12–15 years								
Vaccination program with public funding								
Healthcare professionals								
Older adults aged ≥ 65 years								
Individuals aged 12–64 years								
mRNA-1273								
Market approval								
Approval for individuals aged ≥ 18 years								
Approval for individuals aged 12–17 years								
Vaccination program with public funding								
Older adults aged ≥ 65 years								
Individuals aged 18–64 years								
Individuals aged 12–17 years								
AZD1222								
Market approval								
Approval for individuals aged ≥ 18 years								
Vaccination program with public funding								
Options for individuals aged ≥ 40 years								

Supplementary Figure 1: Timeline of COVID-19 vaccine approval and administration in Japan. *Vaccination of individuals aged 12 to 64 years prioritized those with underlying medical conditions.

The data source was the National Institute of Infectious Diseases, Japan and the Pharmaceuticals and Medica Devices Agency, Japan.